RAS inhibitor dosing: from public PK/PD data to target-coverage scenarios
Public blood–tumor–DUSP6 reconstruction and hypothetical QD/BID comparisons with target turnover, variability and exposure costs.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
What changes in paired tumor immune-expression measurements during nivolumab?
Fixed immune scores in 43 public RNA pairs, with paired change, normalization sensitivity and patient-separated response-association diagnostics.
既存薬の用量比較を、新薬の用量選択にどこまで借りてよいか
既存薬の用量比較を頑健な混合事前分布として新薬の用量選択に借りると、同等なら得は小さく、逆向きなら正選択率が大きく下がった。1群40例では事前分布との食い違いをほぼ検出できない。借用の重みは0.25〜0.5が目安。